Cardiac Tamponade Secondary to Metastasis from Adenocarcinoma of the Parotid Gland
© Barbetakis et al; licensee BioMed Central Ltd. 2003
Received: 10 August 2003
Accepted: 10 October 2003
Published: 10 October 2003
Metastatic involvement of pericardium producing cardiac tamponade is rare. When occurs it is mainly from the lung, breast and the neoplasms of the lymphoreticular system. Hematogenous spread of parotid adenocarcinoma to heart is extremely rare and only two cases have been reported in literature so far.
We report an unusual case of a patient with adenocarcinoma of the parotid gland, which presented with cardiac tamponade and was treated urgently with pericardial drainage and intrapericardial injection of cisplatin.
Our case demonstrates the possibility of metastatic pericardial involvement and cardiac tamponade in patients with parotid adenocarcinoma. The patient was successfully treated with pericardial drainage and intrapericardial injection of chemotherapeutic agent to control recurrent pericardial effusion.
KeywordsParotid neoplasm tumor metastasis heart cardiac tamponade pericardial effusion intrapericardial cisplatinum
A variety of malignant diseases have been reported to metastasize to the pericardium. The ones most commonly reported include bronchial carcinoma, breast cancer, leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, melanoma, gastrointestinal tumors and sarcomas.
Metastatic involvement of the pericardium may occur from either direct invasion by an adjacent primary tumor or by lymphatic or hematogenous spread. We report here a case of hematogenous metastasis to pericardium from adenocarcinoma of the parotid gland.
A 61-year-old woman was admitted with a palpable right parotid mass and peripheral facial nerve palsy. She underwent a radical total parotidectomy with a subsequent diagnosis of high-grade adenocarcinoma of the parotid gland (T2N2BM0 – Stage IV AJCC 1997 . Postoperatively she was treated with adjuvant radiotherapy (parotid bed and neck nodes – 60 Gy over 30 fractions) and 3 cycles of chemotherapy (docetaxel, 100 mg/m2 over 1 hour I.V. injection every 3 weeks) and was followed-up on a routine outpatient basis.
Malignant involvement of the heart or pericardium is not uncommon in patients with advanced cancer. The prevalence of combined metastasis to the pericardium and heart ranges from 0.1% to 21%. The most common malignancies involving the heart or pericardium include lung, breast, leukemia, Hodgkin's and non-Hodgkin's lymphoma, melanoma, gastrointestinal primaries and sarcomas .
The increase in pericardial fluid seen in malignant pericardial effusions is usually due to obstruction of lymphatic and venous drainage of the heart and this disturbs the level of intrapericardial pressure depending on the rate of fluid accumulation, pericardial compliance and intravascular volume. Mediastinal nodal involvement, which is frequently seen with lung and breast cancer, disturbs lymphatic drainage from the heart and pericardium through the cardiac nodes.
Our case demonstrates pericardial involvement and cardiac tamponade in a patient with parotid cancer. According to the international literature, two cases of parotid adenocarcinoma involving the pericardium have been described [3, 4]. Becker et al reported a unique case of malignant pericardial effusion secondary to metastatic mucoepidermoid carcinoma in a patient previously treated for mucoepidermoid carcinoma of the parotid gland and subsequently found to have hypernephroma of the kidney. Surgical intervention and pericardial window formation was ultimately necessary in this case. In the second case Sulkes et al., reported a metastatic pericardial involvement due to parotid adenocarcinoma but without cardiac tamponade and right heart congestive signs. In our case the patient presented with cardiac tamponade and was successfully treated with pericardiocentesis and intrapericardial administration of cisplatin.
The acute treatment of malignant pericardial effusion with cardiac tamponade involves the prompt removal of pericardial fluid by pericardiocentesis usually under echocardiographic guidance. The long-term management however remains controversial. Radiotherapy has been considered effective however it is not used any more. The creation of a pericardial window has been shown to be quite effective and has until recently been considered to be the treatment of choice for malignant pericardial effusion. The procedure requires left anterolateral thoracotomy or subxiphoid approach under general anesthesia and can be associated with significant morbidity and mortality in an already debilitated patient.
Intrapericardial administration of sclerozing agents such as tetracycline, 5 FU, bleomycin, cisplatin, and talc has been used for the palliative treatment of malignant pericardial effusions. Intrapericardial tetracycline has been used extensively with successful long-term control of effusions. Unfortunately, the use of tetracycline has been associated with several complications including arrhythmias, severe pain and fever . We favor intrapericardial instillation of cisplatin, which has been associated with minimal side effects (bleomycin has the same results as that of cisplatin ) [7, 8].
In our case there were no complications except for a mild fever (up to 37.5°C) for 48 hours after the instillation. The patient is alive, free of primary disease-related symptoms with no local or distant recurrence on the follow-up. There were no recurrences of pericardial effusion or compressive-constrictive physiology on repeated echocardiograms.
In summary, this rare case suggests that a malignant pericardial effusion should be considered in the patient with parotid adenocarcinoma who develops cardiac tamponade. Cytologic examination of aspirated cardiac pericardial fluid can confirm the diagnosis. Intrapericardial instillation of sclerosing agents should be considered, especially in patients in whom control of recurrent effusion would significantly add to quality of life or life expectancy.
- Head and Neck tumors – Salivary Glands. In Manual for staging of cancer. 1997, American Joint Committee on Cancer (AJCC) Philadelphia, Lippincott
- Pearson FG: Pericardial disease in thoracic surgery. 2002, New York, Churchill Livingstone, 1619-1620. 2Google Scholar
- Becker S, Reza M, Greenberg S, Stein J: Pericardial effusion secondary to mucoepidermoid carcinoma of the parotid gland. A report of an unusual case. Cancer. 1975, 36: 1080-1085.View ArticlePubMedGoogle Scholar
- Sulkes A, Weshler Z, Dolberg L, Biran S: Isolated pericardial metastasis of parotid tumor origin. Head Neck Surg. 1982, 4: 344-348.View ArticlePubMedGoogle Scholar
- Shephard FA, Ginsberg JS, Evans WK: Tetracycline sclerosis in the management of malignant pericardial effusion. J Clin Oncol. 1985, 3: 1678-1682.Google Scholar
- Maher ER, Buckman R: Intrapericardial instillation of bleomycin in malignant pericardial effusion. Am Heart J. 1986, 11: 613-614.View ArticleGoogle Scholar
- Tomkowski WZ, Filipecki S: Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion in the course of the lung cancer. Lung Cancer. 1997, 16: 215-222. 10.1016/S0169-5002(96)00631-9.View ArticlePubMedGoogle Scholar
- Pavón Jiménez R, García Rubira J, García Martínez J, Sánchez R, Calvo Ry Cruz J: Intrapericardial Cisplatin for Malignant Tamponade. Rev Esp Cardiol. 2000, 53: 587-589.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.